89985-87-5

Usage

Uses

Used in Organic Synthesis:
(S)-Methyl-2-Boc-AMino-4-pentenoic acid is used as a building block for the synthesis of complex organic molecules. Its presence allows for selective functionalization of the amino group without affecting other reactive sites in the molecule, which is crucial for the controlled assembly of larger structures.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, (S)-Methyl-2-Boc-AMino-4-pentenoic acid is used as a reagent in the synthesis of various drugs. The Boc protecting group facilitates the creation of peptide and protein derivatives, which are essential components of many therapeutic agents.
Used in Agrochemical Development:
(S)-Methyl-2-Boc-AMino-4-pentenoic acid is also utilized in the development of agrochemicals. Its role in the synthesis of peptide and protein-based pesticides or other agricultural compounds contributes to the advancement of crop protection and management strategies.
Used in Materials Science:
In the field of materials science, (S)-Methyl-2-Boc-AMino-4-pentenoic acid is employed in the synthesis of novel materials with specific properties. (S)-Methyl-2-Boc-AMino-4-pentenoic acid's ability to be selectively functionalized makes it a valuable component in the development of new materials with tailored characteristics for various applications.

Upstream product

• 186581-53-3 diazomethane 
• 16338-48-0 L-allylglycine 
• 74651-77-7 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 917-57-7 vinyllithium 
• 93267-04-0 N-(tert-butoxycarbonyl)-L-3-iodoalanine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 173723-62-1 (S)-allylglycine methyl ester hydrochloride 
• 90600-20-7 (2S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoic acid 
• 263023-27-4 (2S)-2-[tert-butoxycarbonyl-(4-methoxybenzyl)amino]-4-pentenoic acid methyl ester 
• 67-56-1 methanol 
• 307304-60-5 (2S,4'S,5'R)-2-(N-tert-butoxycarbonylamino)-1-(3',4'-dimethyl-2'-oxo-5'-phenyl-1'-imidazolydinyl)-4-penten-1-one 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 50299-15-5 methyl (S)-allylglycinate 
• 119244-19-8 tert-butyl (S)-2-[(diphenylmethylene)amino]pent-4-enoate 

Downstream Products

• 303139-00-6 methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(4-methoxyphenyl)pentanoate 
• 888330-96-9 (L)-5-(3-bromophenyl)-2-tert-butoxycarbonylamino-4-pentenoic acid methyl ester 
• 116613-81-1 (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate 
• 90600-20-7 (2S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoic acid 
• 204711-97-7 (2S)-2-[(tert-butoxycarbonyl)amino]hept-6-enoic acid 

Relevant academic research and scientific papers

Silole Amino Acids with Aggregation-Induced Emission Features Synthesized by Hydrosilylation

The synthesis of silole amino acids was achieved through hydrosilylation of alkene or alkyne-containing amino acids with 1-methyl-2,3,4,5-tetraphenyl-1H-silole, using Karstedt's catalyst with yield up to 95 % and without epimerization. After selective deprotection of carboxylic acid or amine functions respectively, C- or N-peptide coupling with an alanine moiety proved their possible incorporation into peptides. A model tripeptide was synthesized by solid phase synthesis with the N-Fmoc protected silole amino acid version. The silole moiety can be also grafted on a precursor peptide directly on the solid support. These amino acids and peptides exhibit AIE properties with λem ca. 500 nm and Δλ ca. 100 nm. This approach constitutes an alternative and promising strategy for incorporation of such AIE fluorogens to peptides.

ACYCLIC STEREOCONTROLLED SYNTHESIS OF (-)-DETOXININE

Allylic oxidation of (2S)-N-t-butoxycarbonyl-2-amino-4-pentenoic acid methyl ester afforded, stereoselectively, a (2S,3R)-2-amino-3-hydroxyl derivative, which was converted to the unusual amino acid (-)-detoxinine via a chelation controlled aldol condensation followed by a pyrrolidine ring formation.

Microelectrode Arrays, Dihydroxylation, and the Development of an Orthogonal Safety-Catch Linker

Construction of larger molecular libraries on an addressable microelectrode array requires a method for recovering and characterizing molecules from the surface of any electrode in the array. This method must be orthogonal to the synthetic strategies needed to build the array. We report here a method for achieving this goal that employs the site-selective dihydroxylation reaction of a simple olefin.

Aliphatic chain-containing macrocycles as diazonamide A analogs

[Figure not available: see fulltext.] Aliphatic alkyl chain-containing 12–14-membered macrocycles have been designed as structural analogs of antimitotic natural product diazonamide A. Macrocycles were synthesized from 5-bromooxazole in 7 to 9 linear step

PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

The secondary structure of a heptapeptide containing trifluoromethyl-λ6-tetrafluorosulfanyl substituted amino acids

Site specific introduction of the polar hydrophobic trifluoromethyl-λ6-tetrafluorosulfanyl (CF3SF4) group can effectively control the secondary structure of a heptapeptide, the minimum repeat unit of an α-helix. The struct

Divergent Access to Histone Deacetylase Inhibitory Cyclopeptides via a Late-Stage Cyclopropane Ring Cleavage Strategy. Short Synthesis of Chlamydocin

A unified step-economical strategy for accessing histone deacetylase inhibitory peptides is proposed, based on the late-stage installation of multiple zinc-binding functionalities via the cleavage of the strained cyclopropane ring in the common pluripoten

COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF

A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: [in-line-formulae]R1a—[O]v-(-A-L-)m-A-[O]v—R1b [/in-line-formulae] wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria

A series of novel pyridone conjugated monobactams with various substituents at the (4) position were synthesized and evaluated for their antibacterial activities against a panel of multidrug-resistant (MDR) Gram-negative bacteria in vitro. Compounds 46d, 54 and 75e displayed good to moderate activities against P. aeruginosa, among which the activity of 75e against P. aeruginosa was comparable to that of BAL30072 under iron limitation condition. Compounds 35, 46d, 54, 56a, 56c and 56d exhibited good to excellent antibacterial activities against E. coli and K. pneumoniae, which were comparable or superior to that of BAL30072. In vitro liver microsomal stability was further evaluated and the results manifested that Compounds 35, 46d and 54 were metabolically stable in human liver microsomes.

Tridentate Directing Groups Stabilize 6-Membered Palladacycles in Catalytic Alkene Hydrofunctionalization

Removable tridentate directing groups inspired by pincer ligands have been designed to stabilize otherwise kinetically and thermodynamically disfavored 6-membered alkyl palladacycle intermediates. This family of directing groups enables regioselective remote hydrocarbofunctionalization of several synthetically useful alkene-containing substrate classes, including 4-pentenoic acids, allylic alcohols, homoallyl amines, and bis-homoallylamines, under Pd(II) catalysis. In conjunction with previous findings, we demonstrate regiodivergent hydrofunctionalization of 3-butenoic acid derivatives to afford either Markovnikov or anti-Markovnikov addition products depending on directing group choice. Preliminary mechanistic and computational data are presented to support the proposed catalytic cycle.